ZNF207 and glioblastoma: The finding that nontransformed cells are less sensitive to BUGZ loss/inhibition compared to glioblastoma cells places BUGZ as a novel anticancer target for glioblastoma and other cancers with a compromised kinetochore-microtubule interface (Herman et al, 2015; Toledo et al, 2014).